KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Sarepta Therapeutics (SRPT) over the last 15 years, with Q3 2025 value amounting to -$14.6 million.

  • Sarepta Therapeutics' Cash from Operations rose 7937.03% to -$14.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$244.6 million, marking a year-over-year increase of 3059.69%. This contributed to the annual value of -$205.8 million for FY2024, which is 5892.42% up from last year.
  • Sarepta Therapeutics' Cash from Operations amounted to -$14.6 million in Q3 2025, which was up 7937.03% from $261.3 million recorded in Q2 2025.
  • In the past 5 years, Sarepta Therapeutics' Cash from Operations ranged from a high of $261.3 million in Q2 2025 and a low of -$583.4 million during Q1 2025
  • Moreover, its 5-year median value for Cash from Operations was -$92.4 million (2022), whereas its average is -$95.4 million.
  • Per our database at Business Quant, Sarepta Therapeutics' Cash from Operations tumbled by 21505.15% in 2022 and then skyrocketed by 164900.95% in 2025.
  • Quarter analysis of 5 years shows Sarepta Therapeutics' Cash from Operations stood at -$29.3 million in 2021, then crashed by 215.05% to -$92.4 million in 2022, then surged by 40.84% to -$54.7 million in 2023, then skyrocketed by 268.41% to $92.0 million in 2024, then tumbled by 115.85% to -$14.6 million in 2025.
  • Its Cash from Operations stands at -$14.6 million for Q3 2025, versus $261.3 million for Q2 2025 and -$583.4 million for Q1 2025.